Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

NCT02355431 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study withdrawn before enrolling first patient

Conditions

Solid Tumors and Hematologic Malignancy
NSCLC (Non-small Cell Lung Carcinoma)

Interventions

DRUG: Itacitinib
DRUG: erlotinib
DRUG: placebo

Sponsor

Incyte Corporation